{"id":"W4225123144","doi":"10.1016/j.jtocrr.2022.100332","title":"Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Janssen Pharmaceuticals; NIHR Leicester Clinical Research Facility; Eli Lilly Japan; Chugai Pharmaceutical; Pfizer Japan; Merck Sharp and Dohme; EMD Serono; Genentech; Daiichi-Sankyo; National Institute for Health and Care Research; Exelixis; Kissei; Bristol-Myers Squibb; Society for Academic Continuing Medical Education; Comprehensive Cancer Center, City of Hope; Merck KGaA; Boehringer Ingelheim Japan; Taiho Pharmaceutical; F. Hoffmann-La Roche; Takeda Pharmaceutical Company; Novartis Pharma; AbbVie; Bayer; Gilead Sciences; Roche; Novartis; Kyowa Hakko Kirin; Sanofi; Manchester Biomedical Research Centre; Yuhan; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; AstraZeneca; Ignyta; Ono Pharmaceutical; Eli Lilly and Company","keywords":"ROS1; Medicine; Term (time); Oncology; Internal medicine; Cancer; Adenocarcinoma; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00188299,0.0002362374,0.0006855224,0.0001836154,0.0001932959,0.0005335631,0.0002264173,0.0002986826,0.0009397658],"category_scores_gemma":[0.001450351,0.00007290841,0.000615701,0.0001660752,0.0002178092,0.0004578631,0.0002673668,0.0007407124,0.000186205],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005927583,"about_ca_system_score_gemma":0.0003223612,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003466757,"about_ca_topic_score_gemma":0.0007573575,"domain_scores_codex":[0.9994965,0.0001427668,0.00006419944,0.00007931286,0.0001204871,0.00009671941],"domain_scores_gemma":[0.99897,0.0002935595,0.0003609322,0.00006166118,0.000109197,0.0002045831],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1902062,0.004788673,0.2938681,0.001397458,0.003413566,0.0007534279,0.0003214981,0.005893995,0.02628657,0.0002896002,0.002583737,0.470197],"study_design_scores_gemma":[0.01097643,0.1788946,0.7802021,0.0002675403,0.002247078,0.002061089,0.0002144695,0.003821931,0.01316387,0.0004599564,0.007623318,0.00006758888],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919668,0.006913851,0.00009684944,0.0001049354,0.0000205965,0.000032232,0.0003183704,0.000007018854,0.000539365],"genre_scores_gemma":[0.9980094,0.0009764406,0.00006001281,0.00007322301,0.00003816408,0.000024398,0.0005509011,0.000001643317,0.0002657275],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00188299,"threshold_uncertainty_score":0.009958267,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07867063295629535,"score_gpt":0.4960975451885746,"score_spread":0.4174269122322793,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}